Clinical Trials on Submandibular Gland Resection in Switzerland

Total 577 results

European Organisation for Research and Treatment...

Completed

Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer

Testicular Germ Cell Tumor | Ovarian Cancer | Extragonadal Germ Cell Tumor

France, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Portugal, Greece, Austria
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST 2)

Diabetes Mellitus, Type 2 | Dyslipidemia | Peripheral Vascular Disease | Coronary Arteriosclerosis | Cerebrovascular Accident

Greece, Ireland, Russian Federation, Slovakia, Poland, Hungary, Portugal, Switzerland
Pfizer

Completed

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Macular Edema Associated With Diabetes Mellitus

United States, Colombia, Australia, Germany, Italy, South Africa, Greece, France, Austria, United Kingdom, Denmark, India, Portugal, Brazil, Canada, Czechia, Netherlands, Switzerland
Immunocore Ltd

Recruiting

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Select Advanced Solid Tumors

United States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland
Hoffmann-La Roche

Completed

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Ovarian Cancer

France, Spain, Sweden, Hong Kong, Canada, Switzerland, Estonia, Greece, Russian Federation, Hungary, Austria, Bulgaria, Netherlands, Latvia, Italy, Slovenia, Turkey, Serbia, Israel, Argentina, Brazil, Slovakia, Lithuania, Poland, Portugal, Mexi... and more
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study in Painful Diabetic Neuropathy (COMBO-DN)

Diabetic Neuropathy, Painful

Germany, Italy, Netherlands, Croatia, Australia, France, Turkey, Spain, Canada, Poland, Korea, Republic of, United Kingdom, Sweden, Greece, Mexico, Switzerland
Sanofi

Completed

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist (BRIGHT)

Diabetes Mellitus, Type 2

Israel, Czechia, Greece, Italy, United States, Bulgaria, Croatia, Denmark, France, Hungary, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Puerto Rico, United Kingdom, Argentina, Finland, Serbia, Germany, France, Greece, Netherlands, Switzerland
Janssen Research & Development, LLC
PharmaMar

Completed

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Poland, United Kingdom, China, Switzerland, Israel, South Africa, Australia, Russian Federation, New Zealand
Pfizer

Terminated

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Ovarian Cancer

United States, Canada, United Kingdom, Korea, Republic of, Netherlands, Hong Kong, Singapore, Ireland, Estonia, Japan, Taiwan, Italy, Turkey, Slovakia, Germany, Poland, Switzerland, Croatia, Hungary, Bulgaria, Latvia, Mexico, Romania, Russian Federation and more
Novo Nordisk A/S

Completed

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-6)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Denmark, Sweden, Austria, Germany, Macedonia, The Former Yugoslav Republic of, Slovenia, France, Switzerland, Norway, Spain, Ireland, Finland, Romania
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I)

Hidradenitis Suppurativa

United States, Australia, Belgium, Canada, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Spain, Switzerland, Turkey
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Canada, Colombia, Czech Republic, Finland, Hong Kong, India, Italy, Malaysia, Mexico, Netherlands, Norway, Philippines, Portugal, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United...
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) (COMBINE 2)

Diabetes Mellitus, Type 2

United States, China, Taiwan, Canada, Switzerland, Japan, Brazil, Russian Federation, Hungary, Greece, France, Israel, Sweden, Slovakia
Amgen

Terminated

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
AstraZeneca
Eli Lilly and Company

Completed

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Czech Republic, Italy, Poland, Spain, United Kingdom, Germany, Hungary, Finland, Mexico, Austria, France, Israel, Switzerland, Ireland
NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Ovarian Cancer

United States, Israel, Belgium, Netherlands, Hungary, Germany, Poland, Canada, Austria, Czechia, Italy, Spain, Switzerland
Spruce Biosciences

Terminated

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Congenital Adrenal Hyperplasia

United States, Australia, Brazil, Canada, Denmark, Estonia, Germany, Ireland, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
AstraZeneca

Terminated

GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate

Type 2 Diabetes

Brazil, France, Russian Federation, South Africa, Germany, Malaysia, Finland, Norway, Hong Kong, Canada, Hungary, Portugal, Taiwan, India, Philippines, Switzerland, Indonesia, Singapore
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)

SCLC | Breast | Ovarian | Gastric Cancers

United Kingdom, United States, Korea, Republic of, France, Netherlands, Israel, Switzerland
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, France, Germany, Greece, India, Ireland, Japan, Korea, Republic of, Mexico, Philippines, Slovakia, Slovenia, Switzerland, Taiwan, Turkey, Ukraine
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Diabetes Mellitus Type 2

United States, France, Switzerland, Germany, South Africa, Korea, Republic of, Puerto Rico, Canada, Taiwan, Spain, Poland, Slovakia, Thailand, Mexico, Turkey, Australia, Greece, Norway, Sweden, Peru, Romania, Argentina, United Kingdom
Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Completed

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States, Chile, Hong Kong, Argentina, Austria, Brazil, Canada, Mexico, Peru, Puerto Rico, Philippines, Thailand, Russian Federation, Poland, Germany, Taiwan, Switzerland
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Biogen

Terminated

Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy

Diabetes Mellitus | Small Fiber Neuropathy

Bulgaria, Poland, Spain, United Kingdom, Canada, France, Czechia, Germany, Hungary, Greece, Denmark, Italy, Netherlands, Switzerland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE)

Hidradenitis Suppurativa

Belgium, Italy, United Kingdom, United States, Hungary, Malaysia, Germany, Netherlands, France, Israel, Lebanon, Singapore, Spain, Bulgaria, Lithuania, Argentina, Turkey, Guatemala, Switzerland, Vietnam, Philippines, Croatia, India, S... and more
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Completed

Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Sarcoma | Kidney Cancer | Ovarian Cancer | Endometrial Cancer | Pheochromocytoma

France, Canada, Switzerland, Denmark, Belgium, Netherlands, United Kingdom, Germany, Italy, Slovakia, Spain, Portugal, Austria
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Acromegaly

United States, Germany, Italy, Belgium, Taiwan, Turkey, Switzerland, Israel, Netherlands, Sweden, United Kingdom, Korea, Republic of, Spain, France, Canada, Greece, Russian Federation, Denmark, Mexico, China, Hungary, Norway, Argentina and more
Novartis Pharmaceuticals

Completed

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (SUNSHINE)

Hidradenitis Suppurativa

United States, Spain, Russian Federation, Taiwan, Germany, France, United Kingdom, Korea, Republic of, Japan, Australia, Switzerland, Austria, Italy, Sweden, India, Israel, Mexico, Philippines, Portugal, Turkey, Greece, Hungary, Bul... and more
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD EXT)

Hidradenitis Suppurativa

United States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Spain, Switzerland, Turkey, United Kingdom
Tesaro, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Active, not recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Neoplasms

United States, Spain, Finland, Czechia, Italy, Denmark, Germany, Belgium, Israel, Canada, Russian Federation, Sweden, United Kingdom, Poland, Ireland, Ukraine, France, Norway, Switzerland, Hungary
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Diabetes Mellitus Type 2

Sweden, United States, Mexico, South Africa, Russian Federation, France, Spain, Switzerland, Canada, Finland, New Zealand, Korea, Republic of, Thailand, Israel, Germany, Peru, Australia, Denmark, Italy, Ukraine, Greece, Puerto Rico, Guatemal... and more
GlaxoSmithKline

Completed

AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes

Non-Insulin-Dependent Diabetes Mellitus

Spain, Germany, Belgium, United Kingdom, Ireland, Netherlands, Italy, France, Mexico, Switzerland, Lithuania
AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia
Pfizer

Completed

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

Ovarian Cancer

United States, Canada, Australia, France, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Austria, Denmark, Hungary, Singapore, Hong Kong, Belgium, Japan, Ireland, Italy, Netherlands, Czechia, Poland, Switzerland, Russian... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus (RETAIN)

Diabetic Macular Edema

Belgium, United Kingdom, Netherlands, Ireland, Switzerland, Italy, Hungary, France, Spain, Portugal, Poland, Czech Republic, Greece
Boehringer Ingelheim

Recruiting

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Korea, Republic of, Israel, Spain, Australia, Japan, Italy, Germany, Denmark, Belgium, Lithuania, China, Canada, Malaysia, Singapore, New Zealand, France, Mexico, Netherlands, Greece, United Kingdom, Bulgaria, Philipp... and more
Boehringer Ingelheim
Eli Lilly and Company

Completed

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Philippines, Australia, Hong Kong, Korea, Republic of, Canada, Italy, Malaysia, United Kingdom, Mexico, Greece, Spain, Netherlands, Switzerland, Israel, Portugal, Germany, Finland, Norway, Romania, Sweden, Serbia and more
Amgen

Completed

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (BONAFIDE)

Secondary Hyperparathyroidism

United States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
AstraZeneca

Terminated

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Brazil, Czech Republic, Italy, Korea, Republic of, Russian Federation, South Africa, United Kingdom, Vietnam, Philippines, Malaysia, Estonia, Latvia, Lithuania, Poland, Finland, Canada, Hong Kong, Argentina, Hun... and more
Amgen

Completed

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Hyperparathyroidism | End Stage Renal Disease | Chronic Kidney Disease | Kidney Transplantation | Chronic Renal Failure | Hypophosphatemia | Kidney Disease | Chronic Allograft Nephropathy | Disordered Mineral Metabolism | Post Renal Transplantation

United States, Canada, France, Italy, Belgium, Switzerland, Spain, Australia, Germany, Austria, Poland
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2)

Type 1 Diabetes Mellitus

United States, Germany, Belgium, Canada, Japan, Chile, United Kingdom, Poland, Netherlands, Argentina, Sweden, Russian Federation, Switzerland
Concept Medical Inc.

Active, not recruiting

Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global (ABILITY)

Coronary Artery Disease | Diabetes | Acute Coronary Syndrome

Switzerland, Australia, Korea, Republic of, France, Belgium, Netherlands, United Kingdom, India, Austria, Bangladesh, Brazil, Czechia, Germany, Ireland, Italy, Malaysia, Mexico, Poland, Singapore, Sweden, Taiwan
Novartis Pharmaceuticals

Active, not recruiting

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Belgium, Italy, United Kingdom, Hungary, Malaysia, Russian Federation, Taiwan, Germany, Netherlands, France, Israel, Korea, Republic of, Japan, Lebanon, United States, Australia, Singapore, Spain, Switzerland, Austria, Lithuania, ... and more
AstraZeneca

Terminated

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

Type 2 Diabetes

United States, Brazil, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Vietnam, Germany, Philippines, Malaysia, Sweden, Estonia, Latvia, Lithuania, Finland, Norway and more
NantCell, Inc.
Takeda

Terminated

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (GAMMA)

Cancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine Cancer

Italy, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
AbbVie

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis Suppurativa

United States, Japan, Australia, Canada, Korea, Republic of, New Zealand, Puerto Rico, Spain, Austria, Italy, Bulgaria, Israel, Taiwan, Croatia, Hungary, Netherlands, Switzerland, Germany, Portugal, France, United Kingdom, Czechia, ... and more
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore

Clinical Trials on Submandibular Gland Resection in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations